Skip to main content

This site is currently implementing core features and is not ready for patient use yet.

WCAG 2.1 AA

Accessibility Statement

SafeTripVax is committed to ensuring digital accessibility for people with disabilities. We are continually improving the user experience for everyone and applying the relevant accessibility standards.

Report an Accessibility Issue
WCAG 2.1 AA

This website is partially conformant with WCAG 2.1 level AA. Partially conformant means that some pa...

Keyboard Navigation

Tab: Move focus to the next interactive element

Browser & Assistive Technology Compatibility

Screen readers: JAWS, NVDA, VoiceOver, TalkBack

Accessibility Audit

Last audit date: February 2026

Last updated:

Statement version: 2.0

Compliance Status

This website is partially conformant with WCAG 2.1 level AA. Partially conformant means that some parts of the content do not fully conform to the accessibility standard.

This statement applies to the website safetripvax.com and all its subpages.

Accessibility Standards

  • Sufficient color contrast (minimum 4.5:1 for normal text)
  • Text alternatives for non-text content (images, icons)
  • Clear and consistent navigation structure
  • Resizable text up to 200% without loss of content
  • Visible focus indicators for keyboard navigation
  • Form labels and error messages are clearly associated

This website is assessed against the harmonized European standard EN 301 549 V3.2.1 (2021-03), which incorporates WCAG 2.1 Level AA requirements.

Non-Accessible Content

Perceivable

  • Some third-party embedded maps lack text alternatives (WCAG 1.1.1)
  • Certain PDF documents may not have proper heading structure (WCAG 1.3.1)
  • Some educational videos about travel vaccinations do not yet have captions or transcripts (WCAG 1.2.2). We are adding captions to all video content. Expected completion: Q3 2026.

Operable

  • Some interactive map components may not be fully keyboard-operable (WCAG 2.1.1)
  • Focus order may be inconsistent in some modal dialogs (WCAG 2.4.3)

Understandable

  • Some error messages in forms may not be sufficiently descriptive (WCAG 3.3.3)
  • Language of parts is not always programmatically identified for medical terms (WCAG 3.1.2)

Robust

  • Some dynamically loaded content may not be announced by screen readers immediately (WCAG 4.1.3)

Disproportionate Burden

  • Full remediation of legacy PDF health documents published before 2024. We are systematically converting these to accessible HTML format. Estimated completion: Q2 2026.

Content Not Within Scope

  • Third-party embedded content: Google Maps and YouTube embeds may have accessibility limitations beyond our control. We provide alternative text-based information where possible.
  • External links to WHO, CDC, and other health authority websites — their accessibility is governed by the respective organizations.

Browser & Assistive Technology Compatibility

This website is designed to be compatible with the following assistive technologies:

  • Screen readers: JAWS, NVDA, VoiceOver, TalkBack
  • Screen magnifiers and zoom functionality
  • Voice recognition software
  • Modern browsers: Chrome, Firefox, Safari, Edge (latest 2 versions)

Technical Requirements

  • JavaScript must be enabled for full functionality
  • Cookies must be enabled for authentication features
  • Minimum screen resolution: 320px width
  • Recommended: Modern browser with CSS Grid support

Keyboard Navigation

  • Tab: Move focus to the next interactive element
  • Shift + Tab: Move focus to the previous element
  • Enter/Space: Activate buttons and links
  • Arrow keys: Navigate within menus and lists
  • Escape: Close modals and dropdown menus
  • Skip link available to jump to main content

Known Accessibility Issues

  • Some third-party embedded maps may have limited accessibility
  • PDF documents may not be fully accessible (we are working on alternatives)
  • Some complex data tables may require horizontal scrolling on mobile

We are actively working to resolve these issues and improve overall accessibility.

Assessment Methodology

The accessibility of this website was evaluated using the following methods:

  • Automated testing with axe-core and Lighthouse
  • Manual testing with keyboard-only navigation
  • Screen reader testing with NVDA and VoiceOver
  • Color contrast analysis with WebAIM tools
  • User testing with people who use assistive technologies

Accessibility Audit

  • Last audit date: February 2026
  • Audit methodology: Combination of automated testing (axe-core, Lighthouse) and manual expert review against EN 301 549 / WCAG 2.1 AA criteria.
  • Audit scope: All public-facing pages of safetripvax.com including authentication flows, knowledge base, and booking features.

Feedback Mechanism

We welcome your feedback on the accessibility of SafeTripVax. Please let us know if you encounter accessibility barriers:

  • Email: accessibility@safetripvax.com
  • Contact form: available on the Contact page
  • Phone: available upon request via email

We aim to respond to feedback within 14 business days and to resolve issues within 30 business days where technically feasible.

How to Report an Accessibility Issue

If you encounter accessibility barriers on our website, please submit a report including:

  • The URL of the page where the issue occurred
  • A description of the problem and what you were trying to do
  • The assistive technology you are using (e.g. screen reader, magnifier)
  • Your preferred contact method (email or phone)

Enforcement Procedure

If you are not satisfied with our response to your accessibility complaint, you can escalate through the following steps:

  1. Step 1: Contact us at accessibility@safetripvax.com — we will acknowledge within 7 days and respond within 14 business days.
  2. Step 2: If unresolved, file a complaint with PFRON (State Fund for Rehabilitation of Disabled Persons) as the EAA supervisory body for private-sector services in Poland.
  3. Step 3: Contact UOKiK (Office of Competition and Consumer Protection) for market surveillance matters.
  4. Step 4: For cross-border issues, contact the European Commission or the consumer protection authority in your country.

Statement Preparation

  • This statement was prepared on:
  • Last reviewed on:
  • Prepared by: SafeTripVax Accessibility Team

Statement version: 2.0

This accessibility statement is prepared in accordance with the European Accessibility Act (Directive (EU) 2019/882) and its Polish transposition — the Act of 26 April 2024 on ensuring accessibility requirements (Journal of Laws 2024, item 731). The technical standard applied is EN 301 549 V3.2.1 (2021-03), which incorporates WCAG 2.1 Level AA. As a private-sector service provider, SafeTripVax is subject to the EAA obligations effective since 28 June 2025.

This website is assessed against the harmonized European standard EN 301 549 V3.2.1 (2021-03), which incorporates WCAG 2.1 Level AA requirements.

Enforcement & Supervisory Authority

If you are not satisfied with our response to your accessibility feedback, you may contact:

  • PFRON (State Fund for Rehabilitation of Disabled Persons) — the Polish supervisory body for EAA compliance of private-sector entities. Website: pfron.org.pl | Accessibility Portal: dostepnosc.pfron.org.pl
  • UOKiK (Office of Competition and Consumer Protection) — market surveillance authority in Poland
  • The European Commission for cross-border accessibility issues
  • The consumer ombudsman (rzecznik konsumentów) in your local district

Contact & Feedback

Accessibility contact: SafeTripVax Accessibility Team (accessibility@safetripvax.com)

For accessibility feedback, please contact us at: accessibility@safetripvax.com

We aim to respond to accessibility feedback within 14 business days. If we cannot resolve the issue immediately, we will provide an estimated timeline.

If you are not satisfied with our response, you may escalate to the national market surveillance authority or consumer protection body in your country.